Thalidomide News and Research

RSS
Thalidomide is a drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalidomide belongs to the family of drugs called angiogenesis inhibitors. Also called Thalomid.
Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Researchers explore optimal induction therapies for managing blood cancer

Researchers explore optimal induction therapies for managing blood cancer

VELCADE based regimens are cost-effective for payers and patients, finds study

VELCADE based regimens are cost-effective for payers and patients, finds study

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Scientists solve 50-year-old thalidomide puzzle

Scientists solve 50-year-old thalidomide puzzle

Celgene announces fiscal 2009 third-quarter results

Celgene announces fiscal 2009 third-quarter results

Molecules wrestle for supremacy to dictate the physical state of superstructures

Molecules wrestle for supremacy to dictate the physical state of superstructures

Thalidomide does not improve survival in small cell lung cancer

Thalidomide does not improve survival in small cell lung cancer

Separating the good from the bad

Separating the good from the bad

Is human ‘imperfection’ such a bad thing?

Is human ‘imperfection’ such a bad thing?

Lessons from Northwick Park drug-trial disaster

Lessons from Northwick Park drug-trial disaster

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Controlling the building blocks of life

Controlling the building blocks of life